This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Bladder Cancer
and you are
over 18
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This trial will assess the 6-month complete response rate and toxicity profile of oral dovitinib therapy in BCG-refractory urothelial carcinoma patients with tumors with FGFR3 mutations or over-expression who are ineligible for or refusing cystectomy.

Provided treatments

  • Drug: Dovitinib
Tris trial is registered with FDA with number: NCT01732107. The sponsor of the trial is Noah Hahn, M.D. and it is looking for 13 volunteers for the current phase.
Official trial title:
A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157